IN8BIO INC. - COMMON

IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference

17 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Biotech Showcase 2023 in San Francisco

03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

12 Dec 2022 07:00:10 By Nasdaq GlobeNewswire

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

08 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

10 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

03 Nov 2022 09:10:00 By Nasdaq GlobeNewswire

IN8bio to Present at November Investor Conferences

01 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio to Present at Cantor Oncology & HemOnc Conference

27 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400

15 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

13 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

08 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio to Present at September Investor and Scientific Conferences

30 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering

19 Aug 2022 09:20:47 By Nasdaq GlobeNewswire

IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock

16 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

11 Aug 2022 22:05:00 By Nasdaq GlobeNewswire

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

27 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

21 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

12 Jul 2022 08:00:01 By Nasdaq GlobeNewswire